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Deficient suppression of T cell responses to allergen by CD4
 

 
CD25
 

 
 regulatory T cells has 
been observed in patients with allergic disease. Our current experiments used a mouse model 
of airway inflammation to examine the suppressive activity of allergen-specific CD4
 

 
CD25
 

 
 
T cells in vivo. Transfer of ovalbumin (OVA) peptide–specific CD4
 

 
CD25
 

 
 T cells to OVA-
sensitized mice reduced airway hyperreactivity (AHR), recruitment of eosinophils, and T 
helper type 2 (Th2) cytokine expression in the lung after allergen challenge. This suppression 
was dependent on interleukin (IL) 10 because increased lung expression of IL-10 was 
detected after transfer of CD4
 

 
CD25
 

 
 T cells, and regulation was reversed by anti–IL-10R 
antibody. However, suppression of AHR, airway inflammation, and increased expression of 
IL-10 were still observed when CD4
 

 
CD25
 

 
 T cells from IL-10 gene–deficient mice were 
transferred. Intracellular cytokine staining confirmed that transfer of CD4
 

 
CD25
 

 
 T cells 
induced IL-10 expression in recipient CD4
 

 
 T cells, but no increase in IL-10 expression was 
detected in airway macrophages, dendritic cells, or B cells. These data suggest that 
CD4
 

 
CD25
 

 
 T cells can suppress the Th2 cell–driven response to allergen in vivo by an 
IL-10–dependent mechanism but that IL-10 production by the regulatory T cells themselves 
is not required for such suppression.
 
Asthma, which affects 
 

 
5% of the population
of the Western world, is characterized by
bronchial eosinophilic inflammation and airway
hyperreactivity (AHR). Although it is pre-
dominantly eosinophils that are recruited to
the lung, recent evidence suggests that T cells
play an important effector role in this process
both in human asthma and murine models
because lung eosinophilia and AHR are abro-
gated in T cell–deficient mice (1, 2, 3). T
helper type 2 (Th2) cells release IL-4, IL-5,
and IL-13 and have been shown to mediate
allergic reactions (4). The regulation of T cell
responses is an important process in vivo in
order to provide immunity to invading patho-
gens while preventing excessive inflammatory
responses to self-antigens. There is now increas-
ing evidence of the existence of regulatory T
cell subsets capable of suppressing immune re-
sponses (5). One of the best characterized of
these is the “naturally occurring” CD4
 

 
CD25
 

 
regulatory T cells. The precise mechanisms by
which CD4
 

 
CD25
 

 
 regulatory cells suppress
inflammation are unknown, though there is
evidence for the involvement of IL-10 and
TGF-
 

 
 in some settings, as administration of
antibodies against these cytokines prevent the
abrogation of colitis by CD4
 

 
CD25
 

 
 regulatory
T cells in a mouse model and also block the
suppressor activity of T regulatory cells isolated
from human peripheral blood (6, 7, 8).
Although the ability of CD4
 

 
CD25
 

 
 reg-
ulatory T cells to suppress Th1 cell–mediated
diseases has been extensively studied, their role
in controlling Th2 cell–mediated allergic re-
sponses is the subject of more recent investiga-
tion and have thus far been limited to in vitro
and complex in vivo studies. It has been shown
that CD4
 

 
CD25
 

 
 regulatory T cells isolated
from hay fever patients have an impaired ability
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to suppress proliferation and IL-5 production of CD4
 

 
CD25
 

 
T cells compared with healthy controls (9). Mouse studies have
shown that Th2 cell–polarized CD4
 

 
 T cells depleted of the
CD4
 

 
CD25
 

 
 population resulted in increased airway eosino-
philia compared with unfractionated T cells after adoptive
transfer of the Th2 cells (10). Moreover, double transgenic
mice with T cells that express the T cell receptor for OVA
(DO11.10), as well as OVA targeted to the lung epithelium,
demonstrated pulmonary infiltrates containing CD4
 

 
CD25
 

 
T cells (11). These cells were able to prevent OVA-induced
proliferation of CD4
 

 
CD25
 

 
 cells in vitro. In addition, the
mice were shown to be tolerant to OVA when spleen cells
were removed and challenged ex vivo. However, if exogenous
OVA was given to the mice, AHR still developed, although
lung eosinophilia and ex vivo Th2 responses were reduced. In
a different model, cotransfer of CD4
 

 
CD25
 

 
 T cells with
CD4
 

 
CD25
 

 
 T cells from mice sensitized to OVA into T
cell–deficient Rag
 

 
/
 

 
 hosts inhibited both allergen-induced
airway inflammation and IL-4 expression (12). Although these
studies imply that CD4
 

 
CD25
 

 
 regulatory T cells may have a
beneficial role in suppressing allergen-induced airway inflam-
mation in vivo, this has not yet been clearly demonstrated.
In the present study, we have determined the effect of
allergen-specific CD4
 

 
CD25
 

 
 regulatory T cells on the de-
velopment of allergen-induced pulmonary inflammation us-
ing a well-characterized in vivo murine model involving
systemic sensitization and airway challenge with antigen.
We have demonstrated that transfer of allergen-specific
CD4
 

 
CD25
 

 
 regulatory T cells from DO11.10 transgenic
mice inhibited the classical pathology associated with aller-
gic asthma, namely AHR, lung eosinophilia, and Th2 cyto-
kine production. Blocking experiments determined that
this effect is dependent on IL-10. Moreover, we have
shown that CD4
 

 
CD25
 

 
 regulatory T cells exerted their
suppressive effects in vivo independently of their capacity to
produce IL-10 but induced IL-10 production from recipient
CD4
 

 
 T cells.
 
RESULTS
Allergen-specific CD4
 

 
CD25
 

 
 regulatory T cells suppress 
T cell proliferation in vitro and migrate to the lung in vivo
 
Antigen-specific CD4
 

 
CD25
 

 
 T cells were isolated from
spleen and lymph nodes of DO11.10 
 

 
 TCR transgenic mice.
We confirmed regulatory activity of the isolated cells using in
vitro cultures stimulated with OVA and APCs. The OVA-spe-
cific CD4
 

 
CD25
 

 
 T cells did not themselves proliferate on
stimulation with antigen, but suppressed proliferation of spleno-
cytes from OVA-sensitized BALB/c mice (Fig. S1, available at
http://www.jem.org/cgi/content/full/jem.20051166/DC1).
Allergen-specific CD4
 

 
CD25
 

 
 regulatory cells were
transferred into BALB/c mice 24 h before airway allergen
challenge. Flow cytometric analysis of bronchoalveolar lav-
age (BAL), lung tissue and draining lymph nodes confirmed
that transferred DO11.10 CD4
 

 
CD25
 

 
 cells were present in
the airway lumen, lung, and lymph nodes of OVA-sensitized
mice after allergen challenge (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20051166/DC1). Trans-
ferred cells were not detected in the sham-sensitized mice
that received alum/PBS.
 
CD4
 

 
CD25
 

 
 regulatory T cells suppress AHR and leukocyte 
recruitment in vivo
 
AHR is characteristic of the pulmonary response to inhaled
antigen in sensitized animals. Transfer of CD4
 

 
CD25
 

 
 regu-
latory T cells significantly decreased AHR in OVA-sensitized
mice at a dose of 30 mg/ml methacholine (P 
 

 
 0.05; Fig. 1 A).
Figure 1. OVA-specific CD4CD25 regulatory T cells regulate 
allergen-induced airway inflammation in vivo. OVA-sensitized mice 
received either 5  105 CD4CD25 cells or an equivalent volume of PBS 
and were challenged through the airways with OVA. (A) AHR was measured 
24 h after the final OVA challenge using a Buxco system in which mice 
were exposed to increasing concentrations of methacholine. Values are 
expressed as means  SEM (n  9–12 mice/group from two separate 
experiments). *, P  0.05 compared with OVA-sensitized mice that received 
PBS instead of CD4CD25 cells. (B) Lungs were fixed, sectioned, and 
stained with hemotoxylin and eosin. Representative sections are shown for 
each treatment group. BAL and lung tissue digest cells (C) were isolated as 
described in Materials and methods, and eosinophil numbers were deter-
mined by differential counts. Values are expressed as medians (n  9–12 
mice/group from two separate experiments). *, P  0.05 compared with 
OVA-sensitized mice that received PBS instead of CD4CD25 cells.
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These results were confirmed by direct measurement of lung
resistance (RL) and dynamic compliance (Cdyn; Fig. S3, avail-
able at http://www.jem.org/cgi/content/full/jem.20051166/
DC1). In contrast, transfer of OVA-specific CD4
 

 
CD25
 

 
 T
cells had no effect on increased AHR after allergen challenge
(unpublished data).
Transfer of CD4
 

 
CD25
 

 
 regulatory T cells also signifi-
cantly reduced eosinophil numbers in the airway lumen
(BAL cells) and lung parenchyma of OVA-sensitized and
-challenged mice (P 
 

 
 0.05; Fig. 1, B and C). In contrast,
transfer of CD4
 

 
CD25
 

 
 T cells had no such effect on leu-
kocyte recruitment to the airway lumen after allergen chal-
lenge (unpublished data).
 
Th2 response to allergen challenge is modulated by transfer 
of CD4
 

 
CD25
 

 
 regulatory T cells
 
Th2 cells are important effector cells in the pulmonary aller-
gic response, and, therefore, differences in Th2 cell numbers
could potentially account for the decreases in AHR and
eosinophilia mediated by transfer of CD4
 

 
CD25
 

 
 regula-
tory T cells. Th2 cell numbers were determined in the BAL
and lung tissue by costaining cells with CD4 and the Th2
cell–specific marker T1/ST2 (13). There was an increase in
Th2 (CD4
 

 
T1/ST2
 

 
) cell numbers in the airway lumen
and lung of OVA-sensitized and -challenged mice com-
pared with unsensitized mice 24 h after the final OVA chal-
lenge, and this was significantly reduced by transfer of
CD4
 

 
CD25
 

 
 regulatory T cells (P 
 

 
 0.05; Fig. 2, A and B).
Furthermore, antigen-induced increases in BAL IL-5 and
IL-13 were significantly reduced by transfer of CD4
 

 
CD25
 

 
regulatory T cells in OVA-sensitized mice (P 
 

 
 0.05; Fig. 2
C). Similarly, lung homogenate IL-5 and IL-13 were also
decreased by transfer of CD4
 

 
CD25
 

 
 regulatory T cells
(Fig. 2 D). In contrast, production of the Th1-specific cy-
tokine IFN-
 
	
 
 was unaffected by transfer of CD4
 

 
CD25
 

 
regulatory T cells. Lung IFN-
 
	
 
 levels were increased in
OVA-sensitized mice to 843 
 

 
 94 pg/ml from 620  53
pg/ml in alum controls. However, there was no substantial
difference between OVA-sensitized mice and mice that re-
ceived CD4CD25 cells (838  106 pg/ml).
The chemokines eotaxin/CCL11, MDC/CCL22, and
TARC/CCL17 are thought to be involved in leukocyte re-
cruitment during an allergic response and in particular for
the recruitment of eosinophils and Th2 cells (14). By de-
creasing production of these chemokines, regulatory T cells
could potentially suppress the Th2 response. However, BAL
and lung levels of eotaxin/CCL11, MDC/CCL22, and
TARC/CCL17 were unaffected by transfer of CD4
CD25 regulatory T cells (Fig. S4, available at http://
www.jem.org/cgi/content/full/jem.20051166/DC1, and not
depicted).
Similarly, transfer of CD4CD25 T regulatory cells had
no effect on serum IgE or OVA-specific IgE levels in OVA-
sensitized mice (Fig. S5, available at http://www.jem.org/
cgi/content/full/jem.20051166/DC1).
CD4CD25 T cell transfer increases pulmonary 
IL-10 expression
The regulatory activity of CD4CD25 T cells has been at-
tributed to IL-10 and TGF- in some models (6, 7, 8).
Therefore, these cytokines were measured in BAL fluid and
lung homogenate supernatant 24 h after the final allergen
challenge. The concentration of IL-10 was significantly in-
creased in the BAL and lung of OVA-sensitized mice that
received CD4CD25 regulatory T cells compared with
OVA-sensitized mice that received PBS (P  0.05; Fig. 2, E
and F). In contrast, levels of TGF- were unaffected by
transfer of CD4CD25 regulatory T cells (Fig. 2, E and F).
Suppression of allergic inflammation and AHR by 
CD4CD25 regulatory T cells is IL-10 dependent
Because suppression of Th2 responses after transfer of OVA-
specific CD4CD25 T cells in OVA-sensitized mice was
Figure 2. Transfer of CD4CD25 regulatory T cells reduces Th2 
cell responses in the lung after allergen challenge. BAL (A) and lung 
tissue digest cells (B) were isolated as described in Materials and methods. 
Th2 cell numbers were determined 24 h after the final OVA challenge by 
antibody staining and flow cytometric analysis, as described in Materials 
and methods. Th2 cells were defined as cells that were double-stained
for CD4 and the Th2 cell–specific marker T1/ST2. Data are expressed as 
means  SEM. IL-5 and IL-13 levels measured in BAL fluid (C) and lung
homogenate supernatant (D) by ELISA. IL-10 and active TGF-1 levels were 
measured in BAL fluid (E) and lung homogenate supernatant (F) by ELISA. 
Data are expressed as medians (n  9–12 mice/group from two separate 
experiments). *, P  0.05 compared with OVA-sensitized mice that
received PBS instead of CD4CD25 cells.
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associated with increased expression of IL-10, we investi-
gated the role of IL-10 in regulation. To this end, we ad-
ministered a neutralizing antibody against the IL-10 receptor
during the allergen challenge phase. Anti–IL-10R treatment
completely abrogated the suppression of AHR and lung
eosinophil infiltration by CD4CD25 regulatory cells (Fig.
3, A and B). Moreover, CD4CD25 regulatory T cells
were unable to reduce Th2 cell numbers and IL-5 and IL-13
levels in the lung in the presence of anti–IL-10R (Fig. 3, C
and D, and not depicted). Interestingly, anti–IL-10R treat-
ment had no effect on the increased lung IL-10 levels associ-
ated with CD4CD25 regulatory T cells (Fig. 3 E).
Modulation of allergic inflammation and AHR is not 
dependent on CD4CD25 T cell–derived IL-10
Because we had demonstrated that the inhibition of aller-
gen-induced airway inflammation by CD4CD25 regula-
tory T cells was IL-10 dependent, we investigated whether
production of IL-10 from the regulatory T cells themselves
was necessary for their suppressive activity. We therefore de-
rived CD4CD25 T cells from IL-10/ DO11.10 animals
and transferred them during allergic airway disease. AHR,
eosinophil recruitment, and Th2 cytokine expression were
suppressed after transfer of CD4CD25 regulatory T cells
derived from either wild-type or IL-10–deficient mice (Fig.
4, A–D). Interestingly, transfer of CD4CD25 regulatory
T cells from IL-10 knockout mice still resulted in increased
expression of IL-10 in the lung tissue of allergen-challenged
mice (Fig. 4 E).
IL-10 production from CD4 T cells is increased by transfer 
of CD4CD25 regulatory T cells
Because we had established that IL-10 production from the
CD4CD25 regulatory T cells was not necessary for their
suppressive activity, we sought to determine the source of
Figure 3. Suppression of allergen-induced airway inflammation is 
IL-10 dependent. Mice were treated with anti–IL-10R antibody or control 
Ig during the allergen challenge phase of allergic inflammation. AHR (A) 
and lung eosinophilia (B) were quantified as described in Materials and 
methods. IL-5 (C), IL-13 (D), and IL-10 (E) levels were determined in lung 
homogenate supernatant by ELISA. Data are expressed as means  SEM 
(A) or medians (B–E; n  4–6 mice/group). *, P  0.05 compared with 
OVA-sensitized mice that received PBS and control Ig.
Figure 4. Transfer of IL-10–deficient CD4CD25 regulatory T cells 
suppresses allergen-induced airway inflammation. Mice received either 
wild-type CD4CD25 regulatory T cells, IL-10–deficient CD4CD25 reg-
ulatory T cells, or an equivalent volume of PBS as a control. AHR (A) and 
lung eosinophilia (B) were determined as described in Materials and methods. 
IL-5 (C), IL-13 (D), and IL-10 (E) levels were measured in lung homogenate 
supernatant by ELISA. Data are expressed as means  SEM (A) or medians 
(B-E; n  6–11 mice/group from two separate experiments). *, P  0.05 
compared with OVA-sensitized mice that received PBS instead of 
CD4CD25 cells.
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IL-10 during allergen-induced airway inflammation. Intra-
cellular cytokine analysis of lung tissue digest cells showed
that IL-10 is produced primarily from CD4 T cells (Fig. 5,
A and B). We could not find appreciable IL-10 production
from other cells such as CD8 T cells, macrophages, den-
dritic cells, B cells, or granulocytes during allergic lung in-
flammation. Moreover, transfer of CD4CD25 regulatory
T cells increased the percentage of CD4 cells producing IL-
10 compared with PBS alone (Fig. 5, A and B). This increase
in CD4IL-10 cells was not dependent on the ability of the
transferred CD4CD25 regulatory T cells to produce IL-10
because a similar increase in CD4IL-10 cells was seen after
transfer of IL-10–deficient CD4CD25 regulatory T cells.
Thus, CD4CD25 regulatory T cells suppressed allergen-
induced airway inflammation by inducing IL-10 production
from CD4 cells in the lungs of OVA-sensitized mice.
DISCUSSION
In this paper we show for the first time that allergen-specific
CD4CD25 T regulatory cells can suppress multiple
pathophysiological features of allergic airway disease in vivo.
Transfer of these allergen-specific CD4CD25 T regula-
tory cells reduced AHR, Th2 cell and eosinophil recruit-
ment, and Th2 cytokine secretion. Importantly, we show
that this effect is dependent on IL-10 because a neutralizing
anti–IL-10R antibody abrogated suppression by CD4CD25
regulatory T cells. Moreover these effects were found to be
independent of production of IL-10 by the CD4CD25
regulatory cells themselves.
Previous studies have determined that CD4CD25 reg-
ulatory T cells are able to regulate autoimmune immuno-
pathologies, which are generally of a Th1 cell type (7, 15,
16), although a recent study using a Leishmania major infection
model in SCID mice confirmed that both Th1 and Th2 cell
function can be suppressed by naturally occurring CD4
CD25 T regulatory cells (17). Other studies have implied
that CD4CD25 T cells may be able to suppress some as-
pects of allergic pathology, but these have all involved com-
plex transgenic models or cell transfer into T cell–deficient
recipient mice (10–12). We have shown that transfer of
CD4CD25 T regulatory cells into a classical model of sys-
temic allergen sensitization in immunocompetent mice re-
duces multiple pathophysiological parameters, including both
allergen-induced airway inflammation and AHR. These find-
ings support our conclusions from human studies in vitro,
which argue that an imbalance between suppression and acti-
vation exists in patients with allergic disease (9).
Transfer of allergen-specific CD4CD25 T cells into
OVA-sensitized mice reduced eosinophilia and AHR, to-
gether with Th2 cell numbers and Th2 cytokine produc-
tion. This implies that there is an effect on either Th2 cell
trafficking or in local expansion of allergen-specific Th2 cells.
However, the lack of effect on Th2-attracting chemokines
such as CCL22, CCL17, and CCL11 suggests that Th2 cell
recruitment can still occur. Although we saw decreases in
Th2 cytokine secretion after transfer of CD4CD25 T
cells, there was no accompanying reduction in serum IgE
production. This might seem surprising because CD4
CD25 T cells have previously been reported to suppress
IgE in a transgenic model of hyper IgE (18). In addition, pa-
tients with immunodysregulation, polyendocrinopathy, en-
teropathy, X-linked syndrome who lack CD4CD25 reg-
ulatory T cells because of a mutation in Foxp3 exhibit
elevated serum IgE levels (19). However, IL-10 has been
shown to actually increase IgE production from B cells that
have already switched but inhibits germline class switch (20).
The lack of change in IgE in our model probably reflects the
comparably short time course of the model and the timing of
CD4CD25 T cell transfer.
The mechanism of suppression by allergen-specific CD4
CD25 T regulatory cells is controversial. In vitro, the phe-
nomenon is contact dependent but can be observed in the
Figure 5. IL-10 is produced by CD4 T cells during allergen-induced 
airway inflammation and is increased by transfer of CD4CD25 
regulatory T cells. Lungs were digested with collagenase and DNase as 
described in Materials and methods. Digest cells were stimulated by PMA/
Ionomycin in the presence of Brefeldin A for 6 h. Cells were phenotyped by 
staining for CD4, CD8, CD11b (macrophages), CD11c (dendritic cells), and 
B220 (B cells). Granulocytes were defined by forward and side scatter. (A) Data 
are expressed as median cell types producing IL-10 with interquartile 
range (n  6–14 mice/group in three separate experiments). *, P  0.05 
compared with OVA-sensitized mice that received PBS instead of CD4CD25 
cells. (B) Data are shown as representative FACS plots showing costaining of 
lung tissue digest cells with CD4 and IL-10. Percentages in the top right 
quadrants refer to median percentages of CD4 cells expressing IL-10 
(n  6–14 mice/group).
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absence of either IL-10 or TGF- (9, 21, 22). In contrast, in
vivo experiments in a colitis model suggest that IL-10 and
TGF- are involved in the suppression mediated by these
cells (15). However, the effect may be model dependent be-
cause it was not observed in a gastritis model (23). We show
that IL-10 but not TGF- is up-regulated in the lung after
transfer of allergen-specific CD4CD25 T regulatory cells
and that this is observed together with an abrogation of AHR
and allergic inflammation. Moreover, we highlight the im-
portance of this IL-10 by showing that neutralizing anti–IL-
10R antibody treatment abolished the suppressive effect of
the CD4CD25 regulatory T cells so that AHR, eosino-
philia, and Th2 cytokine levels were comparable to those
seen in the absence of regulatory cells. IL-10 has previously
been reported to be a potential regulatory factor in allergen-
induced airway inflammation because transfer of engineered
IL-10–producing T cells reduced AHR and inflammation in
a murine model (24). Although this study showed that neu-
tralization of IL-10 in the lung worsened allergic inflamma-
tion, we did not find that anti–IL-10R treatment had any ef-
fect on OVA-sensitized mice in the absence of transferred
CD4CD25 regulatory T cells. This may be because of dif-
ferences in the time of IL-10 neutralization. Oh et al. admin-
istered anti–IL-10 during both sensitization and challenge
phases of allergen-induced airway inflammation, whereas we
have blocked during the challenge phase only (24).
We have shown that the suppression by CD4CD25
regulatory T cells was not dependent on IL-10 production
from allergen-specific T regulatory cells themselves, because
the suppressive effect was preserved in CD4CD25 cells
isolated from OVA-transgenic IL-10 / mice. Interestingly,
Asseman et al. previously reported that IL-10/ CD4
CD25 T cells could inhibit colitis induced by transfer of
naive but not antigen-experienced T cells (25). In our
model, suppression was seen after transfer of IL-10/ CD4
CD25 T cells into mice that had been sensitized to OVA
and, thus, presumably OVA-experienced Th2 cells were
present. The differential dependence on IL-10 may reflect
differences in the degree of inflammation and T cell activa-
tion in the gut in the colitis model compared with our lung
model but is in keeping with data from a gastritis model (23).
IL-10 expression in the airway was still elevated after transfer
of IL-10/ CD4CD25 T cells, suggesting that the regu-
latory T cells may induce IL-10 production in another cell
population within the lung. These could be CD4CD25 T
cells, which, in humans, have been reported to acquire a
regulatory phenotype dependent on IL-10 production after
in vitro co-culture with CD4CD25 T cells (26). In addi-
tion, a recent report also suggests that CD4CD25 T cells
might not be the only source of IL-10 in a model of infec-
tious tolerance with CD4CD25 T cells during experi-
mental allergic encephalomyelitis (27). Here, we show for
the first time that the percentage of pulmonary CD4IL-10–
producing cells is increased after transfer of CD4CD25
regulatory T cells in vivo. Although we cannot exclude the
possibility that other cells contribute to IL-10 production,
we did not find expression in macrophages, dendritic cells,
or granulocytes. Interestingly, we found IL-10 production
by CD4 cells was similarly increased after transfer of IL-10–
deficient CD4CD25 regulatory T cells. This implies that
CD4CD25 regulatory T cells suppress inflammation via
induction of IL-10 from CD4 T cells and that production
of IL-10 from the regulatory cells themselves is not required.
Thus, our data may reconcile the apparent contradiction in
previous in vitro and in vivo reports because suppression in
vivo may rely on the induction of IL-10 from recipient
CD4 T cells.
The data presented in this paper suggest that induction of
IL-10 in vivo by T regulatory cells may represent a novel
treatment for allergic asthma. Indeed, it has been previously
demonstrated that nonallergic individuals have a higher per-
centage of allergen-specific IL-10–producing cells, whereas
allergic individuals are characterized by a higher percentage
of allergen-specific IL-4–producing cells (8). Strategies for in-
ducing IL-10 may include expansion of the naturally occur-
ring CD4CD25 population or enhancement of regulatory
T cell function by drugs such as corticosteroids, as shown
previously in vitro (28). Alternatively it may be possible to
induce populations of IL-10–producing or TGF- surface-
positive T regulatory cells in vivo, as has been described in
several different murine systems using mycobacterial expo-
sure, airway allergen delivery before sensitization and chal-
lenge, or in vitro derivation by stimulation in the presence of
immunosuppressive drugs (29, 30, 31, 16). Allergen immu-
notherapy has been used for many years to control symptoms
in a variety of allergic diseases, and current data suggest that
this may induce IL-10–producing regulatory T cell popula-
tions (32, 33). Peptide therapy induced IL-10–producing
regulatory cells in mice (34), and recent data suggest that al-
lergen-derived T cell peptides may also reduce features of
asthma in humans through induction of IL-10 (35).
In conclusion, we provide for the first time direct evi-
dence to show that transfer of allergen-specific CD4
CD25 T regulatory cells to sensitized mice abrogates the
features of allergic airway disease in vivo. These include re-
duced eosinophil and Th2 cell recruitment, AHR, and Th2
cytokine production. Down-regulation of inflammation was
observed with a concomitant increase in pulmonary IL-10
production from CD4 T cells. Blocking studies showed
that the suppressive effect was dependent on IL-10, but, im-
portantly, the effect was not dependent on IL-10 production
from the CD4CD25 regulatory T cells themselves. Thus,
our data suggest that strategies designed to maximize the
function of T regulatory cells in vivo could be of benefit to
allergic asthmatic patients in the future.
MATERIALS AND METHODS
Mice
Female BALB/c mice were purchased from Harlan. As a source of allergen-
specific CD4CD25 regulatory T cells, DO11.10 mice expressing the
transgene for the DO11.10  TCR, which recognizes residues 323–339
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of chicken OVA in association with I-Ad, were used. These mice were
originally generated by D. Loh (Washington University, St. Louis, MO)
(36) and were provided by J. Skok (Imperial College, London, UK). Ani-
mals were housed at the Imperial College London animal facility and were
used at 6–8 wk of age. Food and water were supplied ad libitum. UK
Home Office guidelines for animal welfare based on the Animals (Scientific
Procedures) Act of 1986 were strictly observed. DO11.10 mice crossed to
IL-10–deficient mice on a BALB/c background were a gift of K. Rajewsky
(University of Cologne, Cologne, Germany) (37).
Isolation of CD4CD25 regulatory T cells
DO11.10 and DO11.10 IL-10–deficient mice were killed by cervical dislo-
cation, and OVA-specific CD4CD25 cells were isolated from the spleen
and peripheral lymph nodes using a CD4CD25 regulatory T cell isola-
tion kit according to the manufacturer’s protocol (Miltenyi Biotec). Purity
was assessed by flow cytometric analysis (as described in Staining of BAL...)
and was typically 
90%.
In vitro assessment of regulatory capacity
BALB/c mice were sensitized using OVA (Sigma-Aldrich) at a concentration
of 0.1 mg/mouse in 0.2 ml alum (Au-Gel-S; SERVA Electrophoresis) i.p. 1
wk later, mice were killed by cervical dislocation. Spleens were recovered
from mice, and single-cell suspensions were prepared. Splenocytes were cul-
tured in triplicate at 5  105 splenocytes/well in flat-bottomed 96-well plates
in the presence of complete media alone or with 100 g/ml OVA for 48 h.
Complete media consisted of RPMI 1640 (Sigma-Aldrich) containing 10%
FCS (Invitrogen), 5mM L-glutamine (Invitrogen), and 100 U/ml penicillin
and 100 mg/ml streptomycin (Sigma-Aldrich). The cells were incubated for a
further 18 h in the presence of 1 Ci/well [3H]thymidine (MP Biochemicals)
to quantify cell proliferation. To assess the suppressive capacity of freshly
isolated CD4CD25 regulatory T cells, these cells were isolated from
DO11.10 spleen and peripheral lymph nodes and added at 1.25  105 cells/
well. To assess the proliferative capacity of isolated CD4CD25 cells alone,
splenocytes were irradiated at 3,000 rad and cultured with CD4CD25 cells.
[3H]thymidine incorporation data in cpm was converted to stimulation index
(fold increase  cpm with OVA / cpm of medium only condition).
Induction of AHR and eosinophilia
BALB/c mice were sensitized using OVA at a concentration of 0.1 mg/
mouse in 0.2 ml alum on day 0. Control mice received the same volume of
PBS in alum. On day 6, mice received either 5  105 CD4CD25 cells
intravenously in PBS or the same volume of PBS as a control. In some ex-
periments, OVA-specific CD4CD25 T cells were injected as a further
control. All groups of mice were challenged daily with 5% OVA (aero-
solized for 20 min) via the airways between days 7 and 12. In some experi-
ments, mice were dosed with 250 g anti–IL-10R (1B1.3) 30 min before
the first, third, and fifth OVA challenge. Mice were killed by exsan-
guination under terminal anesthesia at 24 h after the final OVA challenge.
Measurement of AHR
Airway responsiveness was measured in mice 24 h after the final OVA chal-
lenge by recording respiratory pressure curves by whole-body plethysmog-
raphy (Buxco Electronics) in response to inhaled methacholine (Sigma-
Aldrich) at concentrations of 3–30 mg/ml for 1 min, as described previously
(38). Results are shown for Penh after allergen challenge. Penh results were
confirmed by direct measurements of RL and Cdyn in anaesthetized and
tracheostomized mice in response to inhaled methacholine at concentra-
tions of 3–100 mg/ml in a Buxco system (Buxco Electronics) in a modified
version of previously described methods (39).
Cell recovery
Airway lumen. BAL was performed as previously described (3). In brief,
the airways of the mice were lavaged three times with 0.4 ml PBS via a tra-
cheal cannula. BAL fluid was centrifuged at 200 g for 5 min at 4C. Cells
were counted and pelleted onto glass slides by cytocentrifugation (5  104
cells/slide). Differential cell counts were performed on Wright-Giemsa–
stained (Thermo) cytospins. Percentages of eosinophils, lymphocyte/mono-
nuclear cells, neutrophils, and macrophages were determined by counting
their number in eight randomly selected high power fields (40; total area 
0.5 mm2/area) and dividing this number by the total number of cells
counted. To obtain absolute numbers of each leukocyte subtype, these per-
centages were multiplied by the total number of cells obtained in the lavage
fluid. All differential counts were performed blind and in a randomized or-
der at the end of the study by the same observer (J. Kearley).
Lung parenchyma. To disaggregate the cells from the lung tissue, one
lobe (100 mg) of lung was incubated at 37C for 1 h in digest reagent
(0.15 mg/ml collagenase [type D; Roche], 25 g/ml DNase [type 1;
Roche]) in complete media. The recovered cells were filtered through a
70-m nylon sieve (Falcon), washed twice, resuspended in complete media,
and counted in a hemocytometer (VWR). Cytocentrifuge preparations
were prepared and Wright-Giemsa stained, and differential counts were
performed as for BAL.
Draining lymph nodes. Draining lymph nodes were removed, weighed,
and filtered through a 70-m nylon sieve. The resulting single cell suspen-
sion was centrifuged at 200 g for 5 min at 4C, resuspended in complete
media, and counted in a hemocytometer.
Lung tissue histopathology
Lungs were fixed in 10% normal buffed formalin. 4-m paraffin-embedded
sections were stained with hemotoxylin and eosin.
Staining of BAL, lung, and lymph node cells for 
flow cytometric analysis
Suspensions of BAL and lung tissue and lymph node cells were stained in PBS
containing 1% FCS and 0.01% sodium azide. To reduce nonspecific binding,
cells were incubated with rabbit serum (Sigma-Aldrich) for 15 min before
staining. The antibodies used were anti–mouse CD4, anti–mouse CD11b,
anti–mouse CD11c, anti–mouse B220, anti–mouse CD8, anti–mouse IL-10
and its isotype control (all obtained from BD Biosciences), anti–mouse T1/
ST2 (Morwell Diagnostics), and anti–mouse KJ1-26 and its isotype control
(Caltag). Cells were stained for 20 min on ice, washed twice, and fixed in
cellfix (Becton Dickinson). For intracellular cytokine staining, cells were stim-
ulated with PMA/ionomycin (Merck) in the presence of Brefeldin A (Sigma-
Aldrich) for 6 h before extracellular staining. After staining and fixing, cells
were permeabilized using 0.5% saponin (Sigma-Aldrich) and stained with
anti–IL-10 antibody or the appropriate isotype control. Flow cytometric anal-
ysis was performed using a FACSCalibur (Becton Dickinson).
Cytokine analysis
Cytokines were analyzed in BAL samples and lung-tissue homogenate super-
natants. Lung tissue was homogenized at 50 mg/ml in HBSS (Invitrogen)
and centrifuged at 800 g for 10 min and the supernatant wascollected. Paired
antibodies for murine IFN-	 and TGF- (BD Biosciences), IL-5 (Endogen),
eotaxin/CCL11, and TARC/CCL17 (R&D Systems) were used in stan-
dardized sandwich ELISAs according to the manufacturer’s protocol. MDC/
CCL22 levels were measured using a sandwich ELISA generated by coating
ELISA plates with anti–mouse MDC (a gift from ICOS Corp., Bothell,
WA) and detecting bound antibody with biotinylated anti–mouse MDC
(R&D Systems) against a standard curve generated using recombinant MDC
(R&D Systems) as previously described (40). ELISA kits to measure IL-13
and IL-10 were purchased from R&D Systems and eBioscience, respectively,
and were used according to the manufacturer’s protocol.
IgE
Levels of total IgE were measured in serum by ELISA using paired antibod-
ies according to the manufacturer’s instructions (BD Biosciences). Levels of
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anti-OVA IgE were measured in serum and lung homogenate supernatant
by ELISA as described previously (41).
Data analysis
Data are expressed as medians unless otherwise stated. Statistical significance
between groups was tested using a Mann-Whitney U Test. A p-value of
0.05 was considered significant. Graph generation and statistical analysis
were performed by using Prism software (version 4.00; GraphPad).
Online supplemental material
Fig. S1 shows that allergen-specific CD4CD25 regulatory T cells suppress
allergen-induced proliferation in vitro. Fig. S2 shows that allergen-specific
CD4CD25 regulatory T cells are able to migrate to the airway lumen,
lung tissue, and draining lymph nodes in vivo. Fig. S3 shows that transfer of
CD4CD25 regulatory T cells suppresses changes in RL and Cdyn. Fig. S4
shows that proinflammatory chemokine levels in the lung are unaffected by
transfer of CD4CD25 regulatory T cells. Fig. S5 shows that transfer of
CD4CD25 regulatory T cells has no effect on serum IgE levels.
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